International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 4 , Pages 1143-1149 , 15 July 2009

Pretreatment Serum Testosterone and Androgen Deprivation: Effect on Disease Recurrence and Overall Survival in Prostate Cancer Patients Treated With Brachytherapy

  • Al V. Taira, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Washington, Seattle, WA
    • ,
  • Gregory S. Merrick, M.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • Corresponding Author InformationReprint requests to: Gregory S. Merrick, M.D., Schiffler Cancer Center, Wheeling Hospital, Wheeling WV 26003-6300. Tel: (304) 243-3490; Fax: (304) 243-5047
    • ,
  • Robert W. Galbreath, Ph.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Wayne M. Butler, Ph.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Kent E. Wallner, M.D.

      Affiliations

    • Puget Sound Healthcare Corporation, Group Health Cooperative, Seattle, WA
    • ,
  • Zachariah A. Allen, M.S.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Jonathan H. Lief, Ph.D.

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Edward Adamovich, M.D.

      Affiliations

    • Wheeling Hospital, Department of Pathology, Wheeling, WV

Received 10 June 2008 ,Revised 5 August 2008 ,Accepted 3 September 2008.

References 

  1. Matsumoto AM. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci. 2002;57:M76–M99
  2. Miner MM, Sadovsky R. Evolving issues in male hypogonadism: Evaluation, management, and related comorbidities. Cleve Clin J Med. 2007;74(Suppl 3):S38–S46
  3. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. J Am Med Assoc. 2006;295:1288–1299
  4. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116:2694–2701
  5. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75
  6. Shores MM, Matsumoto AM, Sloan KL, et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660–1665
  7. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol. 2000;163:824–827
  8. San Francisco IF, Regan MM, Dewolf WC, et al. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol. 2006;175:1341–1345discussion 1345–1346
  9. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52–58
  10. Zhang PL, Rosen S, Veeramachaneni R, et al. Association between prostate cancer and serum testosterone levels. Prostate. 2002;53:179–182
  11. Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005;47:308–312
  12. Isom-Batz G, Bianco FJ, Kattan MW, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173:1935–1937
  13. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670–1675
  14. Teloken C, Da Ros CT, Caraver F, et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005;174:2178–2180
  15. Yamamoto S, Yonese J, Kawakami S, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52:696–701
  16. Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone—a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology. 1997;49:327–334
  17. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol. 2000;6:78–84
  18. Partin AW, Mangold LA, Lemm DM, et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843–848
  19. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297
  20. Huggins C, Stevens R, Hodges C. Studies on prostatic cancer II: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;209–223
  21. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  22. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. J Am Med Assoc. 2004;292:821–827
  23. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591
  24. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs. radiation alone for prostate cancer: A randomized trial. J Am Med Assoc. 2008;299:289–295
  25. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  26. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261–4267
  27. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–3983
  28. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  29. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500
  30. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425
  31. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524
  32. Merrick GS, Butler WM, Wallner KE, et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:669–677
  33. Beyer DC, McKeough T, Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:1299–1305

 Conflict of interest: none.

PII: S0360-3016(08)03522-0

doi: 10.1016/j.ijrobp.2008.09.046

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 4 , Pages 1143-1149 , 15 July 2009

Article Tools

* Image Usage & Resolution